Trop2-expression in primary vulvar squamous cell carcinoma

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2025-04-03 DOI:10.1016/j.ygyno.2025.03.049

Frederik A. Stuebs , Antje Knöll , Arndt Hartmann , Christian Matek , Nelson John , Lothar Häberle , Matthias W. Beckmann , Ramona Erber , Carlos Bercebal , Carol I. Geppert

{"title":"Trop2-expression in primary vulvar squamous cell carcinoma","authors":"Frederik A. Stuebs , Antje Knöll , Arndt Hartmann , Christian Matek , Nelson John , Lothar Häberle , Matthias W. Beckmann , Ramona Erber , Carlos Bercebal , Carol I. Geppert","doi":"10.1016/j.ygyno.2025.03.049","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Vulvar squamous cell carcinoma (VSCC) is a rare malignant disease but with increasing incidence. Therapeutic options are generally limited to surgery and radio-(chemo)therapy. New strategies for therapy are lacking. Trophoblast cell surface antigen 2 (Trop2) is a new target being used in different tumor entities. The purpose of the current research is to assess the expression of Trop2 in VSCC.</div></div><div><h3>Methods</h3><div>We constructed a next generation tissue micro array (ngTMA) including women with primary VSCC treated between 2000 and 2021 at the Department of Gynecology and Obstetrics, Erlangen University Hospital analyzing the expression of Trop2. Further clinicopathologic characteristics were analyzed: tumor stage, regional lymph node-status, venous-, lymphatic- and perineural sheath invasion, depth of invasion, grading, p16/p53 subtype and tumor infiltration lymphocytes.</div></div><div><h3>Results</h3><div>A total of 217 women were included. Trop2 was expressed in 100 % of VSCC. Women were split in two groups, the “low expression” and the “high expression” groups, according to the median of Trop2 (H-score: 279). p16+/p53- is the most common p16/p53 subtype in patients with high Trop2 expression. Trop2 favored a better prognosis in women with VSCC, hence not clinically impactful for the most common p16−/p53+ subtype.</div></div><div><h3>Conclusion</h3><div>The ubiquitous expression of Trop2 makes it an interesting potential target for the Trop2 directed antibody drug conjugate (ADC) sacituzumab govitecan (SG). Clinical trials evaluating the safety and effectiveness of SG in VSCC are needed.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"196 ","pages":"Pages 78-84"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S009082582500126X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Vulvar squamous cell carcinoma (VSCC) is a rare malignant disease but with increasing incidence. Therapeutic options are generally limited to surgery and radio-(chemo)therapy. New strategies for therapy are lacking. Trophoblast cell surface antigen 2 (Trop2) is a new target being used in different tumor entities. The purpose of the current research is to assess the expression of Trop2 in VSCC.

Methods

We constructed a next generation tissue micro array (ngTMA) including women with primary VSCC treated between 2000 and 2021 at the Department of Gynecology and Obstetrics, Erlangen University Hospital analyzing the expression of Trop2. Further clinicopathologic characteristics were analyzed: tumor stage, regional lymph node-status, venous-, lymphatic- and perineural sheath invasion, depth of invasion, grading, p16/p53 subtype and tumor infiltration lymphocytes.

Results

A total of 217 women were included. Trop2 was expressed in 100 % of VSCC. Women were split in two groups, the “low expression” and the “high expression” groups, according to the median of Trop2 (H-score: 279). p16+/p53- is the most common p16/p53 subtype in patients with high Trop2 expression. Trop2 favored a better prognosis in women with VSCC, hence not clinically impactful for the most common p16−/p53+ subtype.

Conclusion

The ubiquitous expression of Trop2 makes it an interesting potential target for the Trop2 directed antibody drug conjugate (ADC) sacituzumab govitecan (SG). Clinical trials evaluating the safety and effectiveness of SG in VSCC are needed.

查看原文本刊更多论文

trop2在原发性外阴鳞状细胞癌中的表达

目的外阴鳞状细胞癌（VSCC）是一种罕见但发病率不断上升的恶性疾病。治疗选择一般限于手术和放化疗。缺乏新的治疗策略。滋养细胞表面抗原2 （Trophoblast cell surface antigen 2, Trop2）是一种新的靶点，被广泛应用于多种肿瘤。本研究的目的是评估Trop2在VSCC中的表达。方法构建下一代组织微阵列（ngTMA），分析2000 - 2021年在埃尔兰根大学附属医院妇产科治疗的原发性VSCC患者的Trop2表达情况。进一步分析临床病理特征：肿瘤分期、局部淋巴结状况、静脉、淋巴及神经周围鞘浸润、浸润深度、分级、p16/p53亚型及肿瘤浸润淋巴细胞。结果共纳入217名妇女。Trop2在100%的VSCC中表达。根据Trop2的中位数（h值：279），将女性分为“低表达”组和“高表达”组。p16+/p53-是Trop2高表达患者中最常见的p16/p53亚型。Trop2有利于VSCC女性患者更好的预后，因此对最常见的p16−/p53+亚型没有临床影响。结论Trop2的普遍表达使其成为Trop2定向抗体药物偶联物（ADC） sacituzumab govitecan （SG）的一个有趣的潜在靶点。需要临床试验来评估SG治疗VSCC的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy